Innovations • Global Impact • In The News • Our People
AAHI's Immune-Enhancing Platform Technologies Support Diagnosis and Prevention of Neglected Tropical Disease
AAHI scientists take a pragmatic and creative approach to product development to create affordable and temperature stable diagnostic tests and life-saving vaccines and therapeutics that are meaningfully accessible and available to people in rural, remote, and low-resource parts of the world.
The latest scientific breakthroughs at AAHI.
AAHI Explores How Adjuvants Stimulate the Immune System
Christopher Fox, Senior Vice President, Formulations recently explained how various adjuvant formulations enhance the immune response to vaccines in the "Vaccine Adjuvants: Mechanism of Action" chapter of the Royal Society of Chemistry's book Vaccine Development: From Concept to Clinic. Dr. Fox analyses how different adjuvants work, including adjuvants in currently licensed human vaccines and experimental adjuvants in clinical development. Understanding how different adjuvants work to stimulate immune responses informs both innovative development of new adjuvants and optimization of current adjuvant formulations.
AAHI's Nanostructured Lipid Carrier (NLC) outperforms alternative formulation technology as a self-amplifying RNA vehicle
Researchers at Imperial College evaluated multiple RNA delivery vehicles for a self-amplifying RNA (saRNA) vaccine for influenza, specifically studying acute systemic cytokine responses, or inflammation expression. They compared three formulations: a cationic polymer, lipid nanoparticles (LNP used in current mRNA vaccines), and AAHI's NLC, and determined that AAHI's NLC works well relative to the other formulations.
Make your products accessible to those who need them most. Collaborate with AAHI.
Collaboration across communities. Explore AAHI's different areas of impact.
AAHI is awarded $9.9M to develop a nasal spray influenza RNA vaccine through Phase 1 clinical trials
Respiratory viruses pose a unique biological threat to global health. In collaboration with the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), AAHI scientists are developing a prototype intranasal influenza RNA vaccine on AAHI's self-amplifying RNA platform. The vaccine candidate targets both pandemic A(H5N1) and A(H7N9) influenza pathogens and can be easily administered as a nasal spray, to induce a mucosal immune response that may both prevent early infection and curtail viral transmission.
Inventprise commences first-in-human clinical trials of its pneumococcal vaccine candidate, with manufacturing support from AAHI
The biotechnology company Inventprise, based in Redmond, WA, recently announced that its 25-valent pneumococcal conjugate vaccine (IVT PCV-25), developed in collaboration with PATH and with funding support from the Bill & Melinda Gates Foundation, entered the clinic. The pneumococcus bacterium is responsible for an estimated 300,000 deaths per year in children under the age of five. AAHI's GMP manufacturing team prepared the Invetnprise vaccine candidate for clinical trials - filling vials with the vaccine and finishing the process of packaging the vaccine for use.
Help us make impossible vaccines possible.
IN THE NEWS
By Gail Dutton
After much deliberation of a long-term COVID-19 vaccination strategy, the Food and Drug Administration's (FDA) vaccine advisory committee concluded everyone should get an annual COVID vaccine that is tailored to the latest variants. Yet there remains skepticism as to whether the omicron-specific booster shots offer improvement over the original vaccine and whether annual shots are sufficient for the most vulnerable populations as transmission of the virus continues causing further mutations. Dr. Corey Casper, CEO, has shared the uniting views of the FDA that next-generation vaccine development is necessary to stop chasing emergent variants and provide long-term protection.
Collaboration across communities. Explore our different areas of impact.
Openings and Opportunities
The Quality Control Associate I/II will be responsible for performing anlaytical tests, gathering and assessing data from those tests, and writing documentation and reports. The candidate will work in quality control laboratories in a GMP Manufacturing setting.
The Associate / Staff Scientist will be responsible for managing and executing formulation development
and stability studies, including collecting, analyzing, reviewing, and reporting bulk antigen and drug
product characterization for multiple projects.
The Associate / Staff Scientist will be responsible for performing assay development, optimizations and
validations, preparation of blood specimens for ex vivo assays under BSL 2 conditions, performing a
variety of immunological assays, and assisting in drafting manuscripts.
The Senior Scientist joining our RNA vaccine team will be responsible for broadening the applications of
AAHI's RNA vaccine platform to a wide range of infectious disease and oncology targets.
Learn more about our formulation technology
We partner with biotech leaders to develop vaccines and more.
Synthetic TLR4 ligand in squalene nanoemulsion
Synthetic TLR4 ligand in QS- 21 containing liposome
Synthetic TLR4 ligand in aqueous formulation
Dual agonist containing both TLR4 and TLR7/8 ligands
Synthetic TLR7/8 ligand in
Synthetic TLR7/8 ligand
adsorbed to aluminum
Synthetic TLR7/8 ligand in
Nanostructured lipid carrier
See how our formulations are being used.
Sign up to stay in touch!
Get the latest news and updates in your inbox every month and learn more about how our scientists are developing equitably accessible vaccines and therapeutics for people who most need them.